Mednet Logo
HomeHematologyQuestion

How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?

4 Answers
Mednet Member
Mednet Member
Medical Oncology · City of Hope

This is also a tough question. I think patients with autoimmune endocrinopathies (especially Hashimoto’s or Type 1 DM) on stable, longstanding replacement regimens, as well as pre-existing vitiligo, are reasonable candidates for frontline PD-1 based therapies, although they certainly bear very close...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · New York Presbyterian/Weill Cornell Medical Center

In patients with a personal history of active autoimmune disease, I typically recommend treatment with BV and AVD. In young patients, I recommend concomitant BV-AVD, and in older patients, I recommend sequential BV and AVD. In the relapsed/refractory setting, I would cautiously consider using a chec...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Aflac Cancer and Blood Disorders Center/ Children's Healthcare of Atlanta - Egleston

As per the protocol entry criteria for S1826, if a patient themselves has an autoimmune condition, I would not offer them a nivolumab/checkpoint-based regimen. The question of what to do in the setting of a family history: there is no data to answer this accurately- depending on the family history a...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Corewell Health West, Cancer Care and Hematology Sevice Line

Patients with controlled autoimmune conditions or even on low-dose steroids are allowed on AHOD2131, including those on replacement therapy for endocrinopathies. I enrolled a patient on this protocol with controlled IBD (Crohn's), and the patient did well. I offer CPI for patients who meet these cri...

Register or Sign In to see full answer

How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma? | Mednet